6‑gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage

Nekrasov,Kostyantyn  A.; Vikarchuk,Mark  V.; Rudenko,Evgeniya  E.; Ivanitskiy,Igor  V.; Grygorenko,Viacheslav  M.; Danylets,Rostyslav  O.; Kondratov,Alexander  G.; Stoliar,Liubov  A.; Sharopov,Bizhan  R.; Kashuba,Volodymyr  I.

doi:10.3892/ol.2019.11015

6‑gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage

Authors:
- Kostyantyn A. Nekrasov
- Mark V. Vikarchuk
- Evgeniya E. Rudenko
- Igor V. Ivanitskiy
- Viacheslav M. Grygorenko
- Rostyslav O. Danylets
- Alexander G. Kondratov
- Liubov A. Stoliar
- Bizhan R. Sharopov
- Volodymyr I. Kashuba
View Affiliations

Affiliations: Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of The National Academy of Sciences of Ukraine, Kyiv 03143, Ukraine, Department of Reconstructive Urology and New Technologies, State Institution of The NAMSU, Kyiv 04053, Ukraine, Ukrainian Medical Stomatological Academy, Poltava 36000, Ukraine, Department of Nerve and Muscle Physiology, Bogomoletz Institute of Physiology of The National Academy of Sciences of Ukraine, Kyiv 01024, Ukraine
Published online on: October 29, 2019 https://doi.org/10.3892/ol.2019.11015
Pages: 6917-6925

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of prostate cancer (PCa) biomarkers in bodily fluids, a process known as liquid biopsy, is a promising approach and particularly beneficial when performed in urine samples due to their maximal non‑invasiveness requirement of collection. A number of gene panels proposed for this purpose have allowed discrimination between disease‑free prostate and PCa; however, they bear no significant prognostic value. With the purpose to develop a gene panel for PCa diagnosis and prognosis, the methylation status of 17 cancer‑associated genes were analyzed in urine cell‑free DNA obtained from 31 patients with PCa and 33 control individuals using methylation‑specific polymerase chain reaction (MSP). Among these, 13 genes indicated the increase in methylation frequency in patients with PCa compared with controls. No prior association has been reported between adenomatosis polyposis coli 2 (APC2), homeobox A9, Wnt family member 7A (WNT7A) and N‑Myc downstream‑regulated gene 4 protein genes with PCa. The 6‑gene panel consisting of APC2, cadherin 1, forkhead box P1, leucine rich repeat containing 3B, WNT7A and zinc family protein of the cerebellum 4 was subsequently developed providing PCa detection with 78% sensitivity and 100% specificity. The number of genes methylated (NGM) value introduced for this panel was indicated to rise monotonically from 0.27 in control individuals to 4.6 and 4.25 in patients with highly developed and metastatic T2/T3 stage cancer, respectively. Therefore, the approach of defining the NGM value may not only allow for the detection of PCa, but also provide a rough evaluation of tumor malignancy and metastatic potential by non‑invasive MSP analysis of urine samples.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cancer in Ukraine 2012–2013, . Bulletin of National Cancer Registry of Ukraine №15. 17–10. 2017
3	Rao AR, Motiwala HG and Karim OM: The discovery of prostate-specific antigen. BJU Int. 101:5–10. 2008.PubMed/NCBI
4	Nogueira L, Corradi R and Eastham JA: Prostatic specific antigen for prostate cancer detection. Int Braz J Urol. 35:521–532. 2009. View Article : Google Scholar : PubMed/NCBI
5	Loeb S and Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett. 249:30–39. 2007. View Article : Google Scholar : PubMed/NCBI
6	Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA and Hoffman RM: Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 173:866–873. 2013. View Article : Google Scholar : PubMed/NCBI
7	Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR and Hoon DS: Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 55:559–567. 2009. View Article : Google Scholar : PubMed/NCBI
9	Frank S, Nelson P and Vasioukhin V: Recent advances in prostate cancer research: Large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Res. 7(pii): F1000 Faculty Rev. –1173. 2018.
10	Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T and Rubin MA: The mutational landscape of prostate cancer. Eur Urol. 64:567–576. 2013. View Article : Google Scholar : PubMed/NCBI
11	Massie CE, Mills IG and Lynch AG: The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 166:1–15. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lee WH, Isaacs WB, Bova GS and Nelson WG: CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev. 6:443–450. 1997.PubMed/NCBI
13	Li LC: Epigenetics of prostate cancer. Front Biosci. 12:3377–3397. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N: Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
15	Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U, Conteduca V and Casadio V: The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn. 16:1283–1290. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zancan M, Galdi F, Di Tonno F, Mazzariol C, Orlando C, Malentacchi F, Agostini M, Maran M, Del Bianco P, Fabricio AS, et al: Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers. 24:147–155. 2009. View Article : Google Scholar : PubMed/NCBI
17	Su YH, Wang M, Brenner DE, Ng A, Melkonyan H, Umansky S, Syngal S and Block TM: Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 6:101–107. 2004. View Article : Google Scholar : PubMed/NCBI
18	Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L and Kohli M: Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 7:35818–35831. 2016. View Article : Google Scholar : PubMed/NCBI
19	Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV and Laktionov PP: Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci. 1137:222–225. 2008. View Article : Google Scholar : PubMed/NCBI
20	Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB and Sidransky D: Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 7:2727–2730. 2001.PubMed/NCBI
21	Goessl C, Müller M, Heicappell R, Krause H, Straub B, Schrader M and Miller K: DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 58:335–338. 2001. View Article : Google Scholar : PubMed/NCBI
22	Salvi S, Gurioli G, Martignano F, Foca F, Gunelli R, Cicchetti G, De Giorgi U, Zoli W, Calistri D and Casadio V: Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers. 2015:5741202015. View Article : Google Scholar : PubMed/NCBI
23	Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Takahashi S, Homma Y, Urano T, Aburatani H and Inoue S: Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol. 28:2012–2024. 2014. View Article : Google Scholar : PubMed/NCBI
24	Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, et al: Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA. 97:12776–12781. 2000. View Article : Google Scholar : PubMed/NCBI
25	Bhatlekar S, Fields JZ and Boman BM: HOX genes and their role in the development of human cancers. J Mol Med (Berl). 92:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
26	Daly CS, Shaw P, Ordonez LD, Williams GT, Quist J, Grigoriadis A, Van Es JH, Clevers H, Clarke AR and Reed KR: Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium. Oncogene. 36:1793–1803. 2017. View Article : Google Scholar : PubMed/NCBI
27	Phin S, Moore MW and Cotter PD: Genomic rearrangements of PTEN in prostate cancer. Front Oncol. 3:2402013. View Article : Google Scholar : PubMed/NCBI
28	Ding W, Zhang J, Yoon JG, Shi D, Foltz G and Lin B: NDRG4 is downregulated in glioblastoma and inhibits cell proliferation. OMICS. 16:263–267. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kang GH, Lee S, Lee HJ and Hwang KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 202:233–240. 2004. View Article : Google Scholar : PubMed/NCBI
30	Kondratov AG, Stoliar LA, Kvasha SM, Gordiyuk VV, Zgonnyk YM, Gerashchenko AV, Vozianov AF, Rynditch AV, Zabarovsky ER and Kashuba VI: Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas. Mol Med Rep. 5:509–512. 2012.PubMed/NCBI
31	Chen N and Zhou Q: The evolving Gleason grading system. Chin J Cancer Res. 28:58–64. 2016.PubMed/NCBI
32	Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK and Pavone-Macaluso M: The TNM classification of prostate cancer. Prostate Suppl. 4:129–138. 1992. View Article : Google Scholar : PubMed/NCBI
33	Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA and Schalken JA: DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 44:8–16. 2003. View Article : Google Scholar : PubMed/NCBI
34	Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH and Sidransky D: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 23:6569–6575. 2005. View Article : Google Scholar : PubMed/NCBI
35	Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, et al: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 13:1720–1725. 2007. View Article : Google Scholar : PubMed/NCBI